Monogram Orthopaedics Inc(MGRM) 2023 Earnings Summary
Bullish Points:
1. Monogram Orthopaedics generated $628,000 in revenue from the sale of licensed implants in the first six months of 2021.
2. The company had a gross profit of $167,771 for the first six months of 2021.
3. As of June 30, 2021, Monogram Orthopaedics had cash on hand of $6,216,312, positive working capital of approximately $3,782,000, and stockholders' equity of $6,055,159.
4. The company raised approximately $6,668,000 in gross proceeds from the Series B Preferred Stock offering through June 30, 2021.
5. Monogram Orthopaedics plans to submit a first-generation press-fit implant for FDA approval by Q2 2022.
6. The company is focusing on cementless knee fixation and expects procedure volumes to increase, driven by demographic tailwinds and rising adoption of uncemented implant use.
7. Management expects robot adoption to continue, with 514,000 TKA procedures potentially being robotic by 2027.
Bearish Points:
1. Total operating expenses for the six months ended June 30, 2021, were $5,071,553 compared to $4,460,182 for the same period in 2020.
2. The company incurred a net loss of $5,151,838 for the six months ended June 30, 2021, compared to a net loss of $5,210,258 for the same period in 2020.
3. As of June 30, 2021, the company had an accumulated deficit of $17,409,370.
4. The company is dependent on its ongoing financing efforts and believes its existing cash resources may be insufficient to fund its continuing operating losses, capital expenditures, lease and debt payments, and working capital requirements in the future.
The final result you summarize based on positive and negative content needs to be objective, neutral, and dialectical.
For more information, you can read the original text of Monogram Orthopaedics Inc(MGRM)'s financial report: https://www.sec.gov/Archives/edgar/data/1769759/000110465921119732/tm2128484d1_1sa.htm
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
